middle.news
Clarity Pharmaceuticals Advances Clinical Trials Amid Rising Losses
12:32pm on Thursday 27th of August, 2026 AEST
•
Healthcare
Read Story
Clarity Pharmaceuticals Advances Clinical Trials Amid Rising Losses
12:32pm on Thursday 27th of August, 2026 AEST
Key Points
Net loss widened to $107.2 million on increased R&D investment
Revenue rose 68% to $8 million, reflecting growing clinical activity
Multiple Phase III trials underway for prostate cancer and neuroendocrine tumour diagnostics
Strong cash reserves of $178.3 million following $203 million capital raise
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE